Opyl (ASX:OPL) has launched a new company name and brand it says signals its entry into the global digital health and artificial intelligence (AI) market.

Michael Daniell has worked in the medical device industry for 40 years and has extensive executive leadership experience.

AusBiotech has released a new report that shows the life sciences industry will be more impacted than other sectors by cuts to the R&D Tax Incentive.

AusBiotech has released a new report illustrating for the first time the disproportionately-negative effects that the biotech sector faces above other innovative industries, by the proposed changes in the new Research and Development Tax Incentive (RDTI) Bill.

The company said the funds raised via the unsecured converting note issue will be used to drive its go-to-market strategy by adding to the US sales and distribution capability and augmenting the Software-as-a-Service sales platform, as well as continued product research and development. 

Australian life sciences company, QBiotics Group, has announced the publication of positive results from a first-in-human phase 1 clinical trial of its anticancer pharmaceutical, tigilanol tiglate (EBC-46) in EBioMedicine, a peer-reviewed translational biomedical research journal by The Lancet.